The Michigan Alzheimer’s Disease Center conducts and supports innovative memory and aging research that seeks to:
- identify disease modifying treatments
- understand disease mechanisms in AD and other dementias
- define biomarkers for early and accurate detection
- devise effective coping strategies for individuals with memory loss and their care-partners
Despite tremendous recent advances in understanding Alzheimer’s disease and related dementias, there’s still much we do not know about the causes of dementing disorders and how to slow down or prevent them altogether. Clinicians and scientists alike need to take a broad, fresh view of the causes of dementia and the potential routes to better therapy. The MADC is deeply committed to this task. Building from the rich expertise present across the University campus, the MADC strives to foster cutting-edge research toward a better understanding and better treatment of Alzheimer’s disease, Lewy Body Disease, frontotemporal dementia and other related disorders.
Areas of research emphasis include investigations of the quality control machinery that counters aggregated proteins in dementia, imaging studies that seek to improve our ability to diagnose disease earlier and more accurately, and explorations of the interplay between metabolic disorders (e.g. obesity, diabetes) and Alzheimer’s disease. A key part of the MADC mission is to make connections – linking scientists to scientists, clinicians to scientists, volunteers to studies, even programs to programs. Through these connections, we can lower the barriers to solving the challenging problems associated with dementia.
Drug Treatment StudiesRVT-101
This is a Phase 2, double-blind, randomized, placebo-controlled crossover study evaluating the effect of RVT-101 on gait and balance in people with Alzheimer’s disease, Lewy body dementia, or Parkinson’s disease dementia ages 55 to 89. Contact Christine Minderovic at email@example.com or 734-998-8420 or Francesca Picotte at firstname.lastname@example.org or 734-998-8400.
Brain Stimulation Studies
Neuroimaging and Biomarker StudiesExamination of the earliest symptoms and biomarkers of FTLD MAPT carriers
Investigating the earliest clinical features of frontotemporal dementia in an effort to improve early detection of the disease. Study is looking for adults age 18 and older with a family member who has frontotemporal dementia. Contact Stephen Campbell at email@example.com or 734-763-2361.Risk Evaluation and Education of Alzheimer’s Disease – the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
Lifestyle Intervention StudiesUniversity of Michigan Memory and Aging Project (UM-MAP)
Investigating changes in cognitive functioning over time to learn more about normal aging and neurodegenerative diseases. Study is looking for adults with or without cognitive changes over the age of 55. Contact Stephen Campbell at firstname.lastname@example.org or 734-763-2361.Community Urban Electroencephalography Study (CUES)Mind ‘n MOTIONEnhancing Safe Mobility among Older Drivers
Investigating how older drivers might change their driving behavior over time and what influences any changes that might occur. Study is looking for healthy adults age 65 or older. Contact Jennifer Zakrajsek at email@example.com or 734-615-4740.ACT-OUT (Participation in ACTivities and Places OUTside the Home of Older Adults with Dementia)
This study takes place at Wayne State University and is investigating participation in activities and places outside the home of older adults with dementia to examine what people do and where they participate in everyday life as they age. This study involves completing a survey and answering interview questions. The study is looking for adults over the age of 55 who are living with dementia. Contact Susan Lawrence, PhD at firstname.lastname@example.org or 313-577-1217Decision Making for Cardiovascular Therapy in Adults with Mild Cognitive Impairment (MCI DeM)
Investigating what adults with cognitive impairment and the friends or family involved in medical care think about health risks and preferences for medical treatment if they were to become seriously ill because of a heart attack or stroke. Study is looking for adults age 65 or older who have a diagnosis of mild cognitive impairment and are fluent in English. Contact Bailey Green at email@example.com or 734-647-3971.
Caregiver StudiesHealth-Related Quality of Life in Caregivers
Investigating important issues associated with health-related quality of life for care partners and caregivers of individuals with mild cognitive impairment and the effectiveness of a widely used caregiver intervention. Study is looking for care partners and caregivers (spouses, family members, or friends) of someone with mild cognitive impairment age 18 and older. Contact Kaley Angers at firstname.lastname@example.org or 734-763-1356.
Join a Study
Now is the time to join our research team. Research participation is a generous gift – a gift that can be shared with future generations as we pave the way to new discoveries in treatment and prevention.
Research participation contributes to the discovery of new ways to diagnose, treat and support people with Alzheimer’s disease or a related disorder. The University of Michigan Memory and Aging Project (UM-MAP), our primary memory and aging study at the MADC, aims to enhance our understanding of the earliest signs of memory or thinking changes. This study simply evaluates naturally occurring changes in behavior and health status of research volunteers over a period of time. Once you are enrolled in UM-MAP, our study coordinator can connect you to other observational, imaging and clinical drug trials that best fit your interests and needs.
We are currently seeking research volunteers experiencing early signs of memory changes as well as healthy older adults. We understand that participating in research is not always an easy decision. Individuals and their families should carefully consider all of the possible benefits and risks before agreeing to participate.
If you are interested in participating in research, please complete a Research Volunteer Form and mail or email to email@example.com.
Please contact Stephen Campbell at 734-763-2361 with any questions or concerns.
There are over 13 million Americans living with a brain disease or disorder. To find treatments and cures, researchers must study the human brain. The Michigan Brain Bank provides individuals and families an opportunity to contribute to this research effort.
Donated brains are collected and stored by the Michigan Brain Bank to help scientists around the world advance the understanding of brain disease and disorders. You can make a difference and help future generations by generously donating your brain to the Michigan Brain Bank.
If you are interested in donating to the Michigan Brain Bank or would like more information, please call 734-647-7648 or visit the Michigan Brain Bank website.
Ma X, Bai Y, Lin Y, Hong X, Liu T, Ma L, Haacke EM, Zhou J, Wang J, Wang M. Amide proton transfer magnetic resonance imaging in detecting intracranial hemorrhage at different stages: a comparative study with susceptibility weighted imaging. Sci Rep. 2017 Apr 4;7:45696. doi: 10.1038/srep45696. PMID:28374764 PMCID:PMC5379544
Basal LA, Yan Y, Shen Y, Haacke EM, Mehrmohammadi M, Allen MJ.Oxidation-Responsive, EuII/III-Based, Multimodal Contrast Agent for Magnetic Resonance and Photoacoustic Imaging. ACS Omega. 2017 Mar 31;2(3):800-805. doi: 10.1021/acsomega.6b00514. Epub 2017 Mar 6. PMID:28393130 PMCID:PMC5377279
Qian J, Wolters FJ, Beiser A, Haan M, Ikram MA, Karlawish J, Langbaum JB, Neuhaus JM, Reiman EM, *Roberts JS, Seshadri S, Tariot PN, Woods BM, Betensky RA, Blacker D. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. PLoS Med. 2017 Mar 21;14(3):e1002254. doi: 10.1371/journal.pmed.1002254. eCollection 2017 Mar.PMID:28323826 PMCID:PMC5360223
Larson EB, Langa KM. What's the "Take Home" from Research on Dementia Trends? PLoS Med. 2017 Mar 7;14(3):e1002236. doi: 10.1371/journal.pmed.1002236. eCollection 2017 Mar. PMID:28267775 PMCID:PMC5340344
Gardner RC, Langa KM, Yaffe K.Subjective and objective cognitive function among older adults with a history of traumatic brain injury: A population-based cohort study. PLoS Med. 2017 Mar 7;14(3):e1002246. doi: 10.1371/journal.pmed.1002246. eCollection 2017 Mar.PMID:28267747 PMCID:PMC5340352
Maust DT, Langa KM, Blow FC, Kales HC. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. Int J Geriatr Psychiatry. 2017 Feb;32(2):164-174. doi: 10.1002/gps.4452. PMID:26889640 PMCID: PMC4990518
Lindauer A, Seelye A, Lyons B, *Dodge HH, Mattek N, Mincks K, Kaye J, Erten-Lyons D.Dementia Care Comes Home: Patient and Caregiver Assessment via Telemedicine.Gerontologist. 2017 Feb 3. doi: 10.1093/geront/gnw206. PMID:28158415 PMID:PMC5217478
Gupta R, Lan M, Mojsilovic-Petrovic J, Choi WH, Safren N, Barmada S, Lee MJ, Kalb R.The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded <i>C9ORF72</i> Inhibits the Proteasome. eNeuro. 2017 Jan 31;4(1). pii: ENEURO.0249-16.2017. doi: 10.1523/ENEURO.0249-16.2017. eCollection 2017 Jan-Feb.PMID:28197542 PMCID: PMC5282547
Dodge HH, Zhu J, Hughes TF, Snitz BE, Chang CH, Jacobsen EP, Ganguli M. Cohort effects in verbal memory function and practice effects: a population-based study.Int Psychogeriatr. 2017 Jan;29(1):137-148. doi: 10.1017/S1041610216001551. Epub 2016 Oct 11.PMID:27725002 PMCID:PMC5177461
Kelly SC, He B, Perez SE, Ginsberg SD, Mufson EJ, Counts SE. Acta Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease. Neuropathol Commun. 2017 Jan 21;5(1):8. doi: 10.1186/s40478-017-0411-2.PMID:28109312 PMCID:PMC5251221
Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ.Biomarkers for the Early Detection and Progression of Alzheimer's Disease.Neurotherapeutics. 2017 Jan;14(1):35-53. doi: 10.1007/s13311-016-0481-z. Review.PMID:27738903 PMCID: PMC5233625
Langa KM, Larson EB, Crimmins EM, Faul JD, Levine DA, Kabeto MU, Weir DR. A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017 Jan 1;177(1):51-58. doi: 10.1001/jamainternmed.2016.6807. PMID:27893041 PMCID: PMC5195883
McKay, E and Counts, SE. Multi-infarct dementia: a historical perspective. (2017). Dementia and geriatric cognitive disorders extra (In press). Dement Geriatr Cogn Dis Extra
Lichtenberg, P.A. Teresi, J.A., Ocepek-Welikson, K & Eimick, J. Reliability and validity of the Lichtenberg Financial Decision Screening Scale (In press). Innovation in Aging2016
Dodge HH, Zhu J, Woltjer R, Nelson PT, Bennett DA, Cairns NJ, Fardo DW, Kaye JA, Lyons DE, Mattek N, Schneider JA, Silbert LC, Xiong C, Yu L, Schmitt FA, Kryscio RJ, Abner EL. Risk of incident clinical diagnosis of Alzheimer’s disease-type dementia attributable to pathology-confirmed vascular disease.; SMART data consortium. Alzheimers Dement. 2016 Dec 23. pii: S1552-5260(16)33091-6. doi: 10.1016/j.jalz.2016.11.003. [Epub ahead of print] ]PMID: 28017827
Krans A, Kearse MG, Todd PK.Repeat-associated non-AUG translation from antisense CCG repeats in fragile X tremor/ataxia syndrome. Ann Neurol. 2016 Dec;80(6):871-881. doi: 10.1002/ana.24800. Epub 2016 Nov 26. PMID:27761921 PMCID:PMC5177492
Chun SY, Rodriguez CM, Todd PK, Mills RE. SPECtre: a spectral coherence—based classifier of actively translated transcripts from ribosome profiling sequence data. BMC Bioinformatics. 2016 Nov 25;17(1):482. PMID:27884106 PMCID:PMC5123373
Flores BN, Dulchavsky ME, Krans A, Sawaya MR, *Paulson HL, Todd PK, Barmada SJ, Ivanova MI. Distinct C9orf72-Associated Dipeptide Repeat Structures Correlate with Neuronal Toxicity.PLoS One. 2016 Oct 24;11(10):e0165084. doi: 10.1371/journal.pone.0165084.PMID:27776165 PMCID:PMC5077081
Amiri S, *Dinov ID. Comparison of genomic data via statistical distribution.J Theor Biol. 2016 Oct 21;407:318-27. doi: 10.1016/j.jtbi.2016.07.032 PMID:27460589 PMCID: PMC5361063
Dodge HH, Zhu J, Hughes TF, Snitz BE, Chang CH, Jacobsen EP, Ganguli M.Cohort effects in verbal memory function and practice effects: a population-based study.* Int Psychogeriatr. 2017 Jan;29(1):137-148. doi: 10.1017/S1041610216001551. Epub 2016 Oct 11.PMID:27725002 PMCID:PMC5177461
Bikson M, Grossman P, Thomas C, Zannou AL, Jiang J, Adnan T, Mourdoukoutas AP, Kronberg G, Truong D, Boggio P, Brunoni AR, Charvet L, Fregni F, Fritsch B, Gillick B, Hamilton RH, *Hampstead BM, Jankord R, Kirton A, Knotkova H, Liebetanz D, Liu A, Loo C, Nitsche MA, Reis J, Richardson JD, Rotenberg A, Turkeltaub PE, Woods AJ. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-61. doi: 10.1016/j.brs.2016.06.004. Review. PMID:27372845 PMCID:PMC5007190
Zhu F, Panwar B, *Dodge HH, Li H, *Hampstead BM, *Albin RL,* Paulson HL, Guan, Y.COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer's disease. Sci Rep. 2016 Oct 5;6:34567. doi: 10.1038/srep34567.PMID: 27703197 PMCID: PMC5050516
Zhang J, Shi J, Stonnington C, Li Q, Gutman BA, Chen K, Reiman EM, Caselli RJ, Thompson PM, Ye J, Wang Y. Hyperbolic Space Sparse Coding with Its Application on Prediction of Alzheimer's Disease in Mild Cognitive Impairment. Med Image Comput Comput Assist Interv. 2016 Oct;9900:326-334. doi: 10.1007/978-3-319-46720-7_38. PMID:28066843 PMCID: PMC5217478
Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL. Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. ; Dominantly Inherited Alzheimer Network..PLoS One. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669.PMID:27649320 PMCID: PMC5029931
Mufson EJ, Ikonomovic MD, Counts SE, Perez SE, Malek-Ahmadi M, Scheff SW, Ginsberg SD. Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behav Brain Res. 2016 Sep 15;311:54-69. doi: 10.1016/j.bbr.2016.05.030. Review.PMID:27185734 PMCID: PMC4931948
Gawronski KA, Kim ES, Langa KM, Kubzansky LD. Dispositional Optimism and Incidence of Cognitive Impairment in Older Adults.Psychosom Med. 2016 Sep;78(7):819-28. doi: 10.1097/PSY.0000000000000345.PMID:27284699 PMCID: PMC5349707
Díaz-Venegas C, Downer B, Langa KM, Wong R. Racial and ethnic differences in cognitive function among older adults in the USA.Int J Geriatr Psychiatry. 2016. Sep;31(9):1004-12. doi: 10.1002/gps.4410.PMID:26766788 PMCID: PMC4945484
Promjunyakul NO, Lahna DL, Kaye JA, *Dodge HH, Erten-Lyons D, Rooney WD, Silbert LC.Comparison of cerebral blood flow and structural penumbras in relation to white matter hyperintensities: A multi-modal magnetic resonance imaging study. J Cereb Blood Flow Metab. 2016 Sep;36(9):1528-36. doi: 10.1177/0271678X16651268. Epub 2016 Jun 7.PMID:27270266 PMCID:PMC5010096
Reams N, Eckner JT, Almeida AA, Aagesen AL, *Giordani B, *Paulson H, Lorincz MT, Kutcher JS. A clinical approach to the diagnosis of traumatic encephalopathy syndrome: A review. Journal of the American Medical Association: Neurology. 73(6):734-749, 2016. PMID: 27111824 PMCID:PMC49220022015
The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: the COSMIC collaboration
Results from the NACC Uniform Data Set Neuropsychological Battery Crosswalk Study
Is the risk of Alzheimer’s disease and dementia declining?
Trajectory of cognitive decline after incident stroke
US prevalence and predictors of informal caregiving for dementia
Financial decision-making abilities and exploitation in older African Americans: Preliminary validity evidence for the Lichtenberg Financial Decision Rating Scale (LFDRS)
The Paulson-Lichtenberg Frailty Index: evidence for a self-report measure of frailty
Autonomic, behavioral, and subjective pain responses in Alzheimer’s disease
Factors associated with cognitive evaluations in the United States
Patient mood and instrumental activities of daily living in Alzheimer disease: Relationship between patient and caregiver reports
Trajectory of cognitive decline after incident stroke
Dual-tasking gait variability and cognition in late-life depression
RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome
Associations between potentially modifiable risk factors and Alzheimer disease: A Mendelian Randomization Study
Loss of F-box only protein 2 (Fbxo2) disrupts levels and localization of select NMDA receptor subunits, and promotes aberrant synaptic connectivity
A novel Alzheimer disease locus located near the gene encoding tau protein
Structural neuroimaging genetics interactions in Alzheimer’s Disease
Gene interactions and structural brain change in early-onset Alzheimer’s disease subjects using the pipeline environment
Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1
Post-mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications
Educational attainment and motor burden in Parkinson’s disease
Patterns of effective connectivity during memory encoding and retrieval differ between patients with mild cognitive impairment and healthy older adults
Comparing the relationship between subjective memory complaints, objective memory performance, and medial temporal lobe volumes in patients with mild cognitive impairment
Hippocampal plasticity during the progression of Alzheimer’s disease
Evidence for mitochondrial UPR gene activation in familial and sporadic Alzheimer’s disease
Archived StudiesImproving Alertness During Long Drives: A Driving Simulation Study
Principal Investigator (PI): Bruno Giordani, PhD
Co-PI: Carol Persad, PhD
Project Description: This study involves the use of a computerized driving simulator to find out if engaging in simple game-like tasks could promote alertness and improved driving performance in fatigued drivers. The study will take place in 2 separate sessions that will last approximately 2 hours each. Participants will be compensated for their time spent in the study.
Participation Criteria: Persons aged 55-65 years with a valid driver’s license over the past 2 years and driving in past 6 months.NOBLE
Principle Investigator (PI): Judith Heidebrink MD, MS
Project Description: The purpose of this research study is to determine whether an investigational drug, T-817MA (also called “T-817”), is safe and beneficial in delaying or altering the decline in memory and daily functioning when given to people with Alzheimer’s disease (AD). We will also be studying the effect of T-817 on brain magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) biomarkers. The U.S. Food and Drug Administration (FDA) has not approved T-817 for the treatment of AD and we do not know whether daily use of T-817 can change the course of the disease.
Participant Criteria: Male or female 55-85 years old; have AD and are experiencing memory problems; currently taking a medication (donepezil [Aricept®] or rivastigmine transdermal system (Exelon® Patch) or donepezil or Rivastigmine and memantine [Namenda™]) for the treatment of AD; have brain MRI or CT result consistent with Alzheimer’s disease; residing in the community with a designated study partner who will accompany the patient to all clinic visits and participate in the evaluations (see protocol details). You may NOT qualify for participation in this study if you use any drug other than donepezil or Exelon Patch (with or without memantine) for Alzheimer’s disease, including galantamine (razadyne); have other neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, or cerebral tumor; have history of untreated thyroid disorder, Type I diabetes, and insulin-dependent, or uncontrolled Type II diabetes, as determined by the PI (except non-insulin controlled Type II diabetes, whose HbA1c value must be below 8.0 %).
Contact: Kathryn Steen MA, firstname.lastname@example.org 734-736-9909Retaining Identity: Creativity and Caregiving
Principle Investigator (PI): Anne Mondro, MFA, Elaine Reed, BFA
Project Description: The goal of our study is to better understand the role of art in the support network of adults with memory loss and their care partners. In the first four weeks, caregivers will learn how to use art materials, explore their creativity, develop a basic understanding of art and design principles, and build communication skills for working with persons with memory loss through art making and guided discussions. Respite care will be available. In the following four weeks, the caregiver will teach the same projects to their care recipient. Facilitators will help guide the caregiver in how to structure the projects for their partner and aid in providing ways to communicate successfully in leading their partner through the art making. A guided discussion with the group will follow. All sessions will be held at the Turner Senior Resource Center in Ann Arbor. Free, close to the building parking is available. Materials and supplies are free to all participants.
Participation Criteria: Diagnosis of mild to moderate Alzheimer’s disease; 50 years of age or over; fluent in English; a study partner/caregiver is required.
Contact: Annie Hyrila, email@example.com , 734-763-3534
Retaining Identity: Creativity and Caregiving brochure (PDF)The WeCareAdvisor Tool to Assist Families Living with Dementia
Principal Investigator (PI): Helen Kales, MD
Project Description: Our study is currently seeking family caregivers to test the WeCareAdvisor, a customized, easy-to-use, internet-based tool that aims to assist in better understanding and managing behavioral symptoms that are a part of dementia. Participants will be interviewed by telephone and then in their home. If it is determined that the study is right for the caregiver and their family member with dementia, they will be randomly assigned to one of two groups that will test the WeCareAdvsior tool for a one-month period. Group A will receive the WeCareAdvisor and begin their trial testing immediately. Group B will test the WeCareAdvisor after a one-month waiting period. During the one month testing period of the WeCareAdvisor participants will also receive weekly check-in phone calls from a research team member. Participants will be compensated for their time spent in the study.
Participation Criteria: The in-home primary caregiver for a person living with dementia, 21 years of age or older, managing behaviors the caregiver finds challenging and comfortable with technology.
Contact: Molly Turnwald, firstname.lastname@example.org, 734-232-0393FYN
Principal Investigator (PI): Judith Heidebrink MD, MS
Project Description: The purpose of this research study is to determine whether AZD0530 is safe and effective in slowing decline in brain metabolism, memory and daily function in people with Alzheimer’s disease. Researchers believe that AZD0530 works by protecting your brain cells from the damage caused by amyloid protein. Amyloid protein is known to be associated with the development of AD. We will use imaging tests to see if AZD0530 affects brain structure and function, and also look at certain proteins in the blood and spinal fluid (the fluid surrounding the brain and spinal cord) that are associated with Alzheimer’s disease.
Participant Criteria: You must be male or female between the ages of 55-85 and have a diagnosis of Alzheimer’s disease. You must be in good general health and be on stable medications. You must have a study partner who is willing to accompany you to your study visits and monitors your study medication and how you are doing on a day to day basis.Merck 19
Principle Investigator (PI): Judith Heidebrink MD, MS
Project Description: The purpose of the study is to test the safety and efficacy of MK-8931 in the treatment of individuals with amnestic Mild Cognitive Impairment due to Alzheimer’s disease (AD). The study will assess the effects that two doses of MK-8931 have on disease progression.
Participation Criteria: Male or female between the ages of 55 and 85; Mild Cognitive Impairment due to Alzheimer’s Disease; a spouse, friend, relative, or caregiver who is willing to accompany them to all of the study visits, monitor them while they are taking the study drug and communicate changes in the patient’s health status over the period of this study.
Contact: Kathryn Steen MA, email@example.com 734-736-9909BAN2401
Principal Investigator (PI): Nancy Barbas MD, MSW
Project Description: The purpose of the BAN2401 research study is to find out if BAN2401 has a positive effect on a person’s cognitive ability based on a series of specialized cognitive tests. The purpose of this research is also to find out if the study drug is safe and well-tolerated in people with early Alzheimer’s disease. People with Alzheimer’s disease have a build-up of abnormal protein known as amyloid in their brains. BAN2401 is thought to reduce the amount of this abnormal protein. The study drug will be given by injecting it into a vein. Analysis will be performed to find out how much of the study drug is in the blood at different times after the injection.
Participation Criteria: Diagnosis of Mild Cognitive Impairment (MCI) or mild Alzheimer’s disease, male or female between the ages of 50 and 90, and ability to provide written consent
Contact: Amanda Rasnake BSN, RN, CCRP, firstname.lastname@example.org 734-232-2452